Ophthalmology and Optometry Coding Alert

Optimize Reimbursement for Photodynamic Therapy (PDT)

When the federal Food and Drug Administration (FDA) approved verteporfin (Visudyne) this spring for photodynamic therapy (PDT), retinologists were able to start using it on their patients, even though there is no code for the drug or the procedure. By next fall, there may be a specific CPT code for PDT, as well as a HCPCS code for the Visudyne. But if you are providing this service now, how can you bill for it?

The correct way to bill is a combination of 90780 (IV infusion for therapy/diagnosis, administered by physician or under direct supervision of physician; up to one hour) for injection of the medication, 67220 (destruction of localized lesion of choroid [e.g., choroidal neovascularization], one or more session, photocoagulation [e.g., laser, ocular photodynamic therapy]) for the laser, and J3490 (unclassified drugs) for the medication.

New Code Will Have Lower RVU

Local carriers, however, will make their own decisions on coverage and payment. The Health Care Financing Administration (HCFA) has agreed to issue a notice of coverage to local carriers but carriers dont have to abide by it. What HCFA wants is to arrive at a new code with a lesser RVU than is attached to 67220. The American Academy of Ophthalmology (AAO) is working to develop fair work values. Also, PDT will be removed from the code description of 67220.

Paul Fernandes, billing manager for Long Island Vitreo Retinal Consultants, a practice with six ophthalmologists in N.Y. and one of the specialists participating in the clinical trials for Visudyne, has been billing 67220, 90780 and J3490 since April 4. Weve been paid for PDT by commercial payers, but not by Medicare yet, says Fernandes. Im not banking on getting anything back from Medicare. So far, Medicare has asked for fluorescein angiograms, and one carrier has asked for documentation of visual acuity.

The big problem, according to Fernandes, is the cost of the drug $1,200 per dose. I meet with patients who want this procedure and explain that I have to ask them to sign a waiver in case Medicare wont pay for the drug, he says. When I tell them the cost, they are a bit shocked. But they are signing the waiver. Some practices performing PDT are collecting payment for the Visudyne up front, but Fernandes prefers the waiver approach.

Tip: Check with your carrier. Some Medicare carriers require that the patient must have better than 20/200 visual acuity, corrected, to pay 67220. Note that there is no national policy as of yet, so all requirements are by LMRPs.

67220 vs. 67299

HCFA would prefer providers to use 67299 (unlisted procedure, posterior segment), but there is no rule that you have to. The fact is that the descriptor for 67220 specifies [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Ophthalmology and Optometry Coding Alert

View All